John Lincoln, MD, PhD
Basic profileJohn Lincoln is a Neurology physician affiliated with The University of Texas Health Science Center at Houston. OpenAlex indexes 87 publications with 4,560 citations (h-index 22); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Fannin St Ste 1014
Houston, TX 77030
Telephone
832-325-7080Registry record last updated 9 May 2019.
Clinical trials
- Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
Sponsor: The University of Texas Health Science Center, Houston
Overall officialPhase 2TerminatedNCT02466074
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Biogen, Inc.Program year202514 payments$15,150openpaymentsdata.cms.gov ↗
- TG Therapeutics, Inc.Program year202514 payments
- Novartis Pharmaceuticals CorporationProgram year202514 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
54.2%Potassium Channel Blocker11.7%Dalfampridine Er94%Ampyra7%Part D<11 patientsGabapentinoids9.6%Gabapentin65%Pregabalin35%Part D≥34 patients+ 15 more classes in this area
Musculoskeletal
18%gamma-Aminobutyric Acid-ergic Agonist11.5%Baclofen100%Part D≥57 patientsMuscle Relaxant4.3%Cyclobenzaprine Hcl85%Methocarbamol16%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
16%CD20-directed Cytolytic Antibody3.4%Kesimpta Pen71%Ocrevus29%Part D<11 patientsPyrimidine Synthesis Inhibitor3.2%Teriflunomide100%Part D<11 patients+ 8 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
John Reveille, MD
The University of Texas Health Science Center at Houston
Martin Citardi, MD
The University of Texas Health Science Center at Houston
Frank Arnett, MD
The University of Texas Health Science Center at Houston
Jerry Wolinsky, MD
The University of Texas Health Science Center at Houston
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”